key: cord-0767049-w198p145 authors: McGovern, Āine T.; Salisbury, Cleo M.; Nyberg, Gregg B. title: The pandemic and resilience for the future: AccBio 2021 date: 2021-09-24 journal: Biotechnol Prog DOI: 10.1002/btpr.3207 sha: b5898c5716102fb9938e7f5be442eaad67f5423a doc_id: 767049 cord_uid: w198p145 The year 2020 brought the onslaught of a global crisis in the form of the COVID‐19 pandemic. While nearly every facet of everyday life and work was impacted by the pandemic, the biopharmaceutical industry found silver linings in innovation, partnership, and resiliency, all of which contributed to unprecedented speed in developing and delivering vaccines and therapies. The 7th International Conference on Accelerating Biopharmaceutical Development (AccBio 2021) brought together industry leaders to share experiences from the past year and discuss how lessons learned from the pandemic can be carried forward into the future of biopharmaceutical development. Presenters highlighted examples such as introducing biotherapeutics derived from non‐clonal cell pools into the clinic, developing modular or platform technologies, and taking novel risks, among others. These strategies for enabling speed to clinic and launch, as well as for sustaining a robust supply chain, are likely to be integrated into future programs to ensure biomanufacturing resiliency and get medicines to patients faster than pre‐pandemic times. innovations and failures alike. The virtual conference centered around the themes of Speed to Clinic and Launch, and Supply Chain and Logistics ( Figure 1 ). While many of the examples presented at the conference focused on monoclonal antibodies (mAbs) for treatment of COVID-19, the takeaways are applicable to other therapeutic targets and modalities. There is opportunity to embrace an innovative mindset to carry the momentum of the past year into the future, examining every step from molecule selection all the way to the patient to ensure the industry continues to move forward. The biopharmaceutical industry has long been in a race against itself to achieve faster timelines in drug development. Over the past 5 years, companies had already drastically shortened the timelines for mAb candidate discovery to investigational new drug (IND) application from up to 24 months to approximately 10 to 12 months. 7 Time to initial marketing application (IMA) could take a decade. Vaccines often took much longer, given the start-stop nature of a highly derisked development process. Use of nonclonal pools required partnership with the health authorities and innovative mitigations to address potential concerns. Harmon explained that close communication with the FDA on the strategy and use of nonclonal pools during product development provided confidence to both parties. One of the main concerns with non-clonal pools was the risk of product variability and population drift, which was resolved by implementing solutions such as: using frozen cell pools to ensure consistent cell age; establishing stringent in-process controls (e.g., to limit population doublings); and employing extra characterization testing to ensure consistency of product quality and process performance. Comparability risks were addressed by using product quality as the basis for criteria to select the final clone. Paul Lewus of Amgen described employing standard equipment designs that enabled rapid assessment of facility fit. Such approaches provide flexibility to increase DS production capacity (by "scaling out" rather than the traditional "scaling up" approach), expedite equipment purchases, and enable transfer to new facilities without having to perform full validation on new equipment. The trend toward rigorous modularity will likely become the norm, and future technology designs would benefit from demonstrating utility across molecules, modalities, and facilities. Modularity can also be useful in drug product (DP) operations. To collapse timelines to accommodate pandemic speed, companies per- Such timeline agility required an equally agile strategy for risk analysis and mitigation planning, since performing normally sequential activities in parallel increases the number of unknowns at each phase of the process, in addition to potentially increasing the cost. In a pandemic setting, companies and health authorities had to rapidly identify where benefit outweighed potential risks. As Weichang Zhou of WuXi Biologics noted, while companies were willing to accept business risks (e.g., parallel investment), they focused on implementing measures to mitigate potential risks to product quality and patient safety. Similar to the comparability strategy for non-clonal cell pools, assessing product quality attributes across stages of development allowed companies to perform multiple steps in parallel and still maintain confidence in product comparability and overall quality. Often this included performing additional analytical assessments compared to traditional comparability; Regeneron, for instance, performed 12 different mass spectrometry exercises to establish comparability for its antibody cocktail. To As Tongtong Wang of Genentech said during her presentation, "The learning from COVID [from] last year and this year will continue to enhance the agility and speed of biologics for the future." Outside of a pandemic setting, the risk-benefit calculation of speed-enabling decisions will be weighed differently; yet there are numerous innovations and advancements that were born out of extraordinary circumstances that the biopharmaceutical industry will strive to apply as the new normal. One of the biggest questions is whether the sheer speed of drug development achieved during the pandemic can realistically be sustained. Panel discussions among presenters seemed to reach a consensus that no, the speed could not be maintained since the heroic efforts, arduous hours, unlimited budgets, and governmental support necessitated by a pandemic are not realistic during normal times. However, the industry cannot and will not settle for pre-pandemic Bringing together leaders from across the biopharmaceutical industry provided a forum to learn from each other and share best practices and ideas for the future. The pandemic achievements and knowledge shared at AccBio 2021 can be used as stimuli for companies to examine past or current processes to determine areas for improvement. Therein lies an opportunity for companies to proactively identify potential enablers for speed and develop the infrastructure to facilitate the kind of progress inspired by the COVID-19 pandemic. The endeavor for speed in drug development will continue into the future and companies will continuously seek to improve how to achieve it. The camaraderie and competition among biopharmaceutical companies, fortified during cross-industry meetings like AccBio, propel the science forward. As Michael Ku of Pfizer concluded in his talk, "We need to have the courage to advance not only best practices but to co-create the next practices for our industry and deliver hope to patients and their families with velocity." It is not just a matter of improving and quickening the process from molecule discovery to launch, but ensuring supply resilience and maintenance of quality end to end to ensure life-saving medicines are made available to everyone who needs them. In addition to the conference speakers noted in Figure 1 , the authors would like to acknowledge the AccBio 2021 panelists, poster presenters, session chairs, and organizing committee. The authors declare no potential conflict of interest. Aine McGovern: Conceptualization (lead); writingoriginal draft (lead); writingreview and editing (equal). Cleo Salisbury: Conceptualization (supporting); writingreview and editing (equal). Gregg Nyberg: Conceptualization (supporting); writingreview and editing (equal). The peer review history for this article is available at https://publons. com/publon/10.1002/btpr.3207. Data sharing not applicable -no new data generated. Aine T. McGovern https://orcid.org/0000-0002-3083-5610 Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 Return of the coronavirus: 2019-nCoV Origin and evolution of pathogenic coronaviruses World Health Organization. WHO director-general's opening remarks at the media briefing on COVID-19 -11. World Health Organization World Health Organization. WHO coronavirus (COVID-19) dashboard. World Health Organization Innovation in a time of crisis Developing therapeutic monoclonal antibodies at pandemic pace Industry view on the relative importance of 'clonality' of biopharmaceutical-producing cell lines A strategy to accelerate protein production from a pool of clones in Chinese hamster ovary cells for toxicology studies Reshaping cell line development and CMC strategy for fast responses to pandemic outbreak Pharmaceutical compoundingsterile preparations. United States Pharmacopeia Development and licensure of vaccines to prevent COVID-19. US Food and Drug Administration Emergency use authorization for vaccines to prevent COVID-19. US Food and Drug Administration